Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells

被引:19
作者
Ezoulin, MJM
Li, J
Wu, GR
Dong, CZ
Ombetta, JE
Chen, HZ
Massicot, F
Heymans, F
机构
[1] Univ Paris 05, Fac Sci Pharmaceut & Biol, Toxicol Lab, F-75270 Paris, France
[2] Univ Paris 07, Unite Pharmacochim Mol & Syst Membranaires EA2381, F-75251 Paris, France
[3] Univ Med 2, Dept Pharmacol, Shanghai 200025, Peoples R China
[4] Univ Med Xinjian, Coll Pharm, Urumqi 830054, Xinjang, Peoples R China
关键词
acetylcholinesterase inhibitor; tetrahydrofuran derivatives; galanthamine; SK-N-SH cells; oxidative stress;
D O I
10.1016/j.neulet.2005.07.026
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
in the search for highly selective and potent cholinesterase inhibitors (AChEI) being able to improve oxidative injury, PMS777, a tetrahydrofuran derivative, was designed as a novel dual PAF and acetylcholinesterase inhibitor. The aim of this study was to investigate the modulatory effects of PMS777 and galanthamine, another AChEI, on the oxidative injury induced in neuronal cells. The SK-N-SH cells stimulated with LPS + IL-(1 beta) were selected to investigate the direct inhibitory effect of PMS777 and galanthamine. LPS + IL-(1 beta) induced oxidative injury as assessed by ROS production (29%), GSH depletion (11%) and loss of mitochondrial activity (22%). GSH depletion was never decreased by either drug. In contrast, ROS production and mitochondrial activity were totally prevented by addition of PMS777 but not galanthamine. PMS777 also inhibits butylcholinesterase and it shows selectivity for acetylcholinesterase. Thus, this PAF antagonist inaugurates a new type of AChEI, able to fight oxidative injury. Therefore, PMS777 could be of interest on patients with cognitive impairments and inflammatory damage, as in AD. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 33 条
[1]   The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease [J].
Aisen, PS .
LANCET NEUROLOGY, 2002, 1 (05) :279-284
[2]  
AISEN PS, 1997, J NEUROIMMUNOL, V33, P167
[3]   Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? [J].
Benzi, G ;
Moretti, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 346 (01) :1-13
[4]  
Braquet P, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P179
[5]  
Chao JCJ, 2004, WORLD J GASTROENTERO, V10, P37
[6]   FEATURES OF APOPTOTIC CELLS MEASURED BY FLOW-CYTOMETRY [J].
DARZYNKIEWICZ, Z ;
BRUNO, S ;
DELBINO, G ;
GORCZYCA, W ;
HOTZ, MA ;
LASSOTA, P ;
TRAGANOS, F .
CYTOMETRY, 1992, 13 (08) :795-808
[7]   A NEW AND RAPID COLORIMETRIC DETERMINATION OF ACETYLCHOLINESTERASE ACTIVITY [J].
ELLMAN, GL ;
COURTNEY, KD ;
ANDRES, V ;
FEATHERSTONE, RM .
BIOCHEMICAL PHARMACOLOGY, 1961, 7 (02) :88-&
[8]  
Giacobini E, 2004, MIL DRUG TH, P11
[9]  
GREIG NH, 2002, DRUG TODAY, V40, P711
[10]   Synthesis and structure-activity relationships of open D-ring galanthamine analogues [J].
Herlem, D ;
Martin, MT ;
Thal, C ;
Guillou, C .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (14) :2389-2391